Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) but cut the price target to $465 from $500. The new price outlook comes on Alnylam Pharmaceuticals announcing strategic priorities for the year, including achieving revenue of $5.1 billion, exceeding the consensus estimate of $4.7 billion. While there have been concerns about November performance, it was mostly affected by one-time factors, including fewer selling days. In the long term, the company is targeting 25% compound annual growth rate through 2030, which aligns with revenue of $11.2 billion. On the other hand, Cantor Fitzgerald has reiterated its Neutral rating on Alnylam Pharmaceuticals. The cautious outlook comes on Amvuttra cardiomyopathy sales slowing down in November but rebounding in December. The company expects Amvuttra's net price to decline by mid-single digits in 2026. The sales patterns and pricing strategy provide context for the research firm's neutral stance. Alnylam Pharmaceuticals, Inc. (N
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Morgan Stanley from $495.00 to $408.00. They now have an "equal weight" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at HC Wainwright from $570.00 to $510.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Bank of America Corporation from $529.00 to $462.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- ALNY's page on the SEC website